home / stock / pasg / pasg news

PASG News and Press, Passage Bio Inc. From 11/10/20

Stock Information
Company Name: Passage Bio Inc.
Stock Symbol: PASG
Market: NASDAQ
Website: passagebio.com
Menu
PASG PASG Quote PASG Short PASG News PASG Articles PASG Message Board
Get PASG Alerts

News, Short Squeeze, Breakout and More Instantly...
PASG - Passage Bio EPS beats by $0.13

Passage Bio (PASG): Q3 GAAP EPS of -$0.63 beats by $0.13.Cash, cash equivalents and marketable securities of $335.7MPress Release For further details see: Passage Bio EPS beats by $0.13

PASG - Passage Bio Reports Third Quarter 2020 Financial Results and Recent Business Highlights

– Dosing for first patient in PBGM01 Phase 1/2 trial anticipated in 1Q2021; initial safety and biomarker data expected mid-year 2021 – – Phase 1/2 clinical trials for FTD-GRN and Krabbe expected to initiate in 1H21 – – Completion of...

PASG - Passage Bio and Invitae Announce Collaboration to Facilitate Genetic Testing to Support Early Diagnosis and Greater Awareness of Clinical Trials for Patients with GM1

PHILADELPHIA, Nov. 09, 2020 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a genetic medicines company focused on developing transformative therapies for rare, monogenic central nervous system disorders, and Invitae (NYSE: NVTA), a leading medical genetics company, announce a collabo...

PASG - Passage Bio to Report Third Quarter 2020 Financial Results on November 10, 2020

PHILADELPHIA, Nov. 04, 2020 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a genetic medicines company focused on developing transformative therapies for rare, monogenic central nervous system disorders, today announced that it will host a conference call and live webcast at 8:30 a.m...
PASG - Passage Bio's PBKR03 nabs Orphan drug tag and accelerated review status for Krabbe disease

The FDA has granted Orphan Drug and Rare Pediatric Disease ((RPD)) designations to Passage Bio's (PASG) PBKR03 for the treatment of Krabbe disease (Globoid Cell Leukodystrophy), a rare and often life-threatening lysosomal storage disease resulting in progressive damage to brain and peripheral...

PASG - Passage Bio's PBKR03 Receives Orphan Drug and Rare Pediatric Disease Designations from FDA for Treatment of Krabbe Disease

PHILADELPHIA, Oct. 28, 2020 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a genetic medicines company focused on developing transformative therapies for rare, monogenic central nervous system disorders, today announced that the U.S. Food and Drug Administration (FDA) has granted Orp...

PASG - Passage Bio's lead gene therapy an Orphan Drug in Europe for rare nerve cell disease

The European Commission has designated Orphan Drug status to Passage Bio's (PASG) PBGM01 for the treatment of GM1 gangliosidosis (GM1)PBGM01, an adeno-associated virus-delivery gene therapy, and has previously been granted Orphan Drug and Rare Pediatric Disease designation in the U.S. for the...
PASG - Passage Bio's PBGM01 Receives Orphan Drug Designation from EMA for Treatment of GM1 Gangliosidosis

PHILADELPHIA, Oct. 26, 2020 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a genetic medicines company focused on developing transformative therapies for rare, monogenic central nervous system disorders, today announced that the European Commission (EC) has granted orphan drug design...

PASG - Passage Bio's PBGM01 shows encouraging pre-clinical benefits in murine model of GM1 gangliosidosis

Passage Bio (PASG) announces publication of data in a murine model of GM1 gangliosidosis (GM1) demonstrating that a single intracerebroventricular injection of an optimized adeno-associated virus (PBGM01) into the cerebral spinal fluid ((CSF)) resulted in significant expression of Beta-g...

PASG - Passage Bio Announces Publication of Preclinical Data That Show Single Injection of Optimized AAV Vector into Cerebral Spinal Fluid Corrects Neurological Disease, Supporting Advancement of PBGM01 into Clinic

PHILADELPHIA, Oct. 13, 2020 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a genetic medicines company focused on developing transformative therapies for rare, monogenic central nervous system disorders, today announced publication of data in a murine model of GM1 gangliosidosis (GM1...
Previous 10 Next 10